ABT-199–based therapies for neuroblastoma in adults and children
Official title: ABT-199 based therapies to treat neuroblastoma
Funded at Virginia Commonwealth University · NIH-11387752 · Data updated 2026-11-12
A cancer researcher is testing venetoclax (a BCL-2 inhibitor) in neuroblastoma to see if it works better when combined with targeted drugs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project start | April 1, 2017 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $492,086 |
| NIH project number | 5R01CA215610-07 |
| Project ID | NIH-11387752 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with high-risk neuroblastoma or relapsed disease who may benefit from future trials of VEN-based combinations.
✕Less likely to help
Patients with neuroblastoma who do not respond to BCL-2–targeted strategies or who cannot tolerate these drug combinations may not benefit.
What this research studies
This project focuses on high-risk neuroblastoma, a deadly pediatric cancer, and explores combinations of venetoclax with SHP2 inhibitors and BCL-xL–targeting antibody-drug conjugates. The research uses preclinical models to test drug partnerships and identify effective treatment strategies. The goal is to translate promising lab findings into clinically relevant options that could help patients with relapsed or hard-to-treat neuroblastoma.
Why it matters
Potential benefit: If successful, this work could lead to more effective combination therapies for neuroblastoma, potentially improving survival and quality of life for patients.
How similar studies have gone: Previous studies have shown VEN can partner with other drugs in neuroblastoma models, supporting a rational combination approach.
Where this research is happening
-
Virginia Commonwealth University
Richmond, United States Active
Researchers
- Principal investigator: Faber, Anthony Charles — Virginia Commonwealth University
- Study coordinator: Faber, Anthony Charles
Related research
Other NIH-funded projects on the same topics.
-
Computational and functional screens to find actionable neuroblastoma drivers
Researchers are using advanced computer analysis and lab tests to find new genes and drug targets in neuroblastoma, aiming to improve outcomes for children.
-
Understanding ATRX in neuroblastoma: new protein functions and treatment clues
A short, patient-friendly look at a study exploring how altered ATRX proteins in neuroblastoma might influence disease behavior and response to therapy.
-
Neuroblastoma and radiopharmaceuticals: understanding how targeted radiation affects kids’ tumors
A pediatric cancer grant studies how a targeted radiotherapy called 131I-MIBG affects tumor and surrounding cells in children with high-risk neuroblastoma.
-
Bispecific antibodies to help kids fight neuroblastoma and brain tumors
A pediatric-focused grant tests new bispecific antibodies that help the immune system attack childhood cancers like neuroblastoma and brain tumors.
-
ADEPT-STAR therapy for high risk neuroblastoma
A new cell-based therapy approach aims to help children with high-risk neuroblastoma by using off-the-shelf, donor-derived treatments.
-
MYCN and ferroptosis: a new vulnerability in pediatric neuroblastoma
A study in children with neuroblastoma looks at a new vulnerability called ferroptosis that could be exploited to more effectively treat tumors with the MYCN gene amplification.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.